title: Medicoeconomic evaluation of hyaluronic acid for knee osteoarthritis in everyday practice: the MESSAGE study.
abstract: BACKGROUND
  Medicoeconomic data on treatments for osteoarthritis are scant. We investigated the impact of hyaluronic acid therapy on the cost of management of knee osteoarthritis. Our primary objective was to compare medical costs (admissions, outpatient visits, investigations, and treatments) and non-medical costs (sick leaves and transportation) from the perspective of the national health insurance system during the 3 months before and the 6 months after three intraarticular injections of hyaluronic acid. Our secondary objective was to evaluate treatment benefits in terms of pain, function, and quality of life.
  
  
  METHODS
  Observational, multicenter, longitudinal, before-after study of the medical and economic effects of hyaluronic acid therapy for symptomatic knee osteoarthritis.
  
  
  RESULTS
  Of the 296 assessable patients (mean age, 69 years; 30% with obesity; 65% women), only 5% of patients were withdrawn prematurely from the study. Significant improvements in the Lequesne index were found 3 and 6 months after treatment; the improvement was greater than 50% in over half the patients. Pain and quality-of-life scores improved significantly. Total cost of the disease decreased from 334 euros for the 3 pretreatment months to 295 euros and 233 euros for posttreatment months 1-3 and 4-6, respectively.
  
  
  CONCLUSIONS
  The costs of knee osteoarthritis decreased during the 6 months after Suplasyn therapy, indicating that the cost of the medication was more than offset by the decreased need for other treatments. Concomitantly, clinical benefits were obtained. Under the conditions of everyday practice, hyaluronic acid may provide medical benefits at an acceptable cost.
authors.affiliation: Rheumatology Department, Rangueil Teaching Hospital, Toulouse, France. mazieres@cict.fr
authors.forename: Bernard
authors.initials: B
authors.lastname: Mazières
authors.forename: Hervé
authors.initials: H
authors.lastname: Bard
authors.forename: Marie
authors.initials: M
authors.lastname: Ligier
authors.forename: Isabelle
authors.initials: I
authors.lastname: Bru
authors.forename: Geneviève Giret
authors.initials: GG
authors.lastname: d'Orsay
authors.forename: Claude
authors.initials: C
authors.lastname: Le Pen
mesh_terms: D000368:Aged; D017281:Cost of Illness; D005260:Female; D005602:France / Q000453:epidemiology; D006801:Humans; D006820:Hyaluronic Acid / Q000191:economics* / Q000627:therapeutic use*; D008137:Longitudinal Studies; D008297:Male; D010003:Osteoarthritis / Q000188:drug therapy* / Q000191:economics* / Q000453:epidemiology; D020370:Osteoarthritis, Knee / Q000188:drug therapy* / Q000191:economics / Q000453:epidemiology; D010146:Pain; D010147:Pain Measurement; D011788:Quality of Life; D013222:State Medicine
chemical_list: D006820:Hyaluronic Acid